Allakos Inc

NASDAQ ALLK

Data sourced from

and

Download Data

Allakos Inc EBIT Ratio 1 year YoY Change (%) for the quarter ending September 19, 2024

Allakos Inc EBIT Ratio 1 year YoY Change (%) is NA for the quarter ending September 19, 2024. EBIT Ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

NASDAQ: ALLK

Allakos Inc

CEO	Dr. Robert Alexander Ph.D.
IPO Date	July 19, 2018
Location	United States
Headquarters	975 Island Drive, Redwood City, CA, United States, 94065
Employees	131
Sector	Healthcare
Industry	Biotechnology

Description

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Key trends